Cargando…
Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center
BACKGROUND: Local treatment in pelvic Ewing sarcoma (ES) consists of operation, radiation therapy, or a combination of both. Reported outcomes vary depending on the treatment modality performed. It is the objective of this study to analyze surgical outcome and complications as well as oncological ou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667797/ https://www.ncbi.nlm.nih.gov/pubmed/33198775 http://dx.doi.org/10.1186/s13018-020-02028-3 |
_version_ | 1783610385155227648 |
---|---|
author | Guder, Wiebke K. Hardes, Jendrik Nottrott, Markus Steffen, Anne Juliane Dirksen, Uta Streitbürger, Arne |
author_facet | Guder, Wiebke K. Hardes, Jendrik Nottrott, Markus Steffen, Anne Juliane Dirksen, Uta Streitbürger, Arne |
author_sort | Guder, Wiebke K. |
collection | PubMed |
description | BACKGROUND: Local treatment in pelvic Ewing sarcoma (ES) consists of operation, radiation therapy, or a combination of both. Reported outcomes vary depending on the treatment modality performed. It is the objective of this study to analyze surgical outcome and complications as well as oncological outcome and complications of chemo- and radiation therapy in this patient cohort and evaluate prognostic factors. METHODS: Retrospective review of 104 patients who underwent tumor resection for pelvic ES from 1988 to 2014. RESULTS: All patients underwent pelvic resection and radiation therapy was administered in 77.9%. Margins were clear in 94.2%. The response to chemotherapy was good in 78.8%. Local recurrence occurred in 7.7%. The presence of distant metastases at the time of operation was the most important negative predictor for overall survival (p = 0.003). The cumulative 5- and 10-year survival rates were 82.7% and 80.1% for non-metastasized and 61.4% and 41.6% for metastasized pelvic ES at operation. In the presence of a single-distant metastatic site at operation compared to multiple metastatic sites, the cumulative survival rates were 64.3% versus 50% at five and 50.7% versus 16.7% at 10 years. CONCLUSIONS: A combined treatment approach of tumor resection and radiation therapy leads to a local control and overall survival rates comparable with those of extremity locations in this study’s patient cohort with localized pelvic ES. Therefore, surgical tumor resection (combined with (neo-)adjuvant radiation therapy) in non-metastatic pelvic ES seems feasible. In metastatic patients, however, the significance of tumor resection as a part of local treatment remains less certain and improved outcomes of combined local treatment approaches need to be weighed against these patients’ prognosis and quality of life. |
format | Online Article Text |
id | pubmed-7667797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76677972020-11-17 Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center Guder, Wiebke K. Hardes, Jendrik Nottrott, Markus Steffen, Anne Juliane Dirksen, Uta Streitbürger, Arne J Orthop Surg Res Research Article BACKGROUND: Local treatment in pelvic Ewing sarcoma (ES) consists of operation, radiation therapy, or a combination of both. Reported outcomes vary depending on the treatment modality performed. It is the objective of this study to analyze surgical outcome and complications as well as oncological outcome and complications of chemo- and radiation therapy in this patient cohort and evaluate prognostic factors. METHODS: Retrospective review of 104 patients who underwent tumor resection for pelvic ES from 1988 to 2014. RESULTS: All patients underwent pelvic resection and radiation therapy was administered in 77.9%. Margins were clear in 94.2%. The response to chemotherapy was good in 78.8%. Local recurrence occurred in 7.7%. The presence of distant metastases at the time of operation was the most important negative predictor for overall survival (p = 0.003). The cumulative 5- and 10-year survival rates were 82.7% and 80.1% for non-metastasized and 61.4% and 41.6% for metastasized pelvic ES at operation. In the presence of a single-distant metastatic site at operation compared to multiple metastatic sites, the cumulative survival rates were 64.3% versus 50% at five and 50.7% versus 16.7% at 10 years. CONCLUSIONS: A combined treatment approach of tumor resection and radiation therapy leads to a local control and overall survival rates comparable with those of extremity locations in this study’s patient cohort with localized pelvic ES. Therefore, surgical tumor resection (combined with (neo-)adjuvant radiation therapy) in non-metastatic pelvic ES seems feasible. In metastatic patients, however, the significance of tumor resection as a part of local treatment remains less certain and improved outcomes of combined local treatment approaches need to be weighed against these patients’ prognosis and quality of life. BioMed Central 2020-11-16 /pmc/articles/PMC7667797/ /pubmed/33198775 http://dx.doi.org/10.1186/s13018-020-02028-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Guder, Wiebke K. Hardes, Jendrik Nottrott, Markus Steffen, Anne Juliane Dirksen, Uta Streitbürger, Arne Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title | Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title_full | Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title_fullStr | Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title_full_unstemmed | Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title_short | Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
title_sort | pelvic ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667797/ https://www.ncbi.nlm.nih.gov/pubmed/33198775 http://dx.doi.org/10.1186/s13018-020-02028-3 |
work_keys_str_mv | AT guderwiebkek pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter AT hardesjendrik pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter AT nottrottmarkus pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter AT steffenannejuliane pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter AT dirksenuta pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter AT streitburgerarne pelvicewingsarcomaaretrospectiveoutcomeanalysisof104patientswhounderwentpelvictumorresectionatasinglesupraregionalcenter |